News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Resverlogix Corporation (RVX.TO) Establishes Subsidiary: RVX Therapeutics Inc. (RVX)



10/19/2005 5:09:04 PM

CALGARY, ALBERTA--(CCNMatthews - July 29, 2005) - Resverlogix Corp. (TSX:RVX) is pleased to announce that it has established a wholly-owned subsidiary called RVX Therapeutics Inc. for business and strategic objectives. Resverlogix Corp. will still hold its primary asset - NEXVAS(TM) technology for cardiovascular applications. The purpose of RVX Therapeutics is to hold non-core assets (TGF-Beta Shield(TM) and others) that will develop separately from the NEXVAS technology. An independent third-party valuation group has been hired to provide the appropriate valuation for the transfer of this technology. This process is planned to occur imminently.

Read at CCNMatthews


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES